Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

PHASE2RecruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

February 14, 2026

Study Completion Date

July 1, 2026

Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
DRUG

Brentuximab vedotin

Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)

Trial Locations (1)

N6A 4V2

RECRUITING

Rheumatology Clinic, St. Joseph's Health Care, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seattle Genetics (now a wholly owned subsidiary of Pfizer)

UNKNOWN

collaborator

Pfizer

INDUSTRY

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT05149768 - Open Label Extension Study of Brentuximab Vedotin in Early dcSSc | Biotech Hunter | Biotech Hunter